BRISBANE, Calif.–(BUSINESS WIRE)–Jan. 4, 2019– Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global investment firm.

“The addition of the KKR loan financing to Aimmune’s capital resources is expected to fully fund the commercialization of AR101, an investigational biologic oral immunotherapy for the treatment of peanut allergy,” said Eric Bjerkholt, Chief Financial Officer of Aimmune Therapeutics. “In addition, this financing secures resources to support the continued advancement of our pipeline of additional food allergy treatments, including the Phase 2 trial of AR201 for egg allergy, which is anticipated to commence this year.”

In December 2018, Aimmune submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration(FDA) for AR101 for the treatment of peanut allergy in children and adolescents ages 4–17 years based on data from the landmark Phase 3 PALISADE trial, which met its primary and key secondary endpoints, and from additional ongoing and completed AR101 clinical trials. The FDA has granted Breakthrough Therapy Designation to AR101 for the desensitization of peanut-allergic patients 4–17 years of age.

The loan agreement provides Aimmune with an up to $170 million term loan in three tranches. Forty million dollars was funded at close, with $85 million to follow upon FDA approval of AR101 and satisfaction of other customary borrowing conditions, and $45 million at the company’s option in 2020 upon the satisfaction of certain borrowing conditions. The loan can be prepaid at Aimmune’s discretion, at any time, subject to prepayment fees. Further information with respect to the term loan is set forth in a Form 8-K filed by Aimmune with the Securities and Exchange Commission on January 4, 2019.

Aimmune reported September 30, 2018, cash, cash equivalents and short-term investments of $255 million. With the $98 million equity investment from Nestlé Health Science announced in November 2018 and the $170 million KKR loan, assuming full borrowings under all tranches, Aimmune’s capital resources as of September 30, 2018, would have exceeded $500 million.

For KKR, the investment is part of the firm’s Health Care Royalty and Income strategy, which is focused on providing non-dilutive capital to companies for which KKR can help reach scale and achieve strategic objectives.

“Aimmune is leading the way in meeting the critical, growing need to offer treatment to the millions of people affected by food allergies,” said Emily Janvey, M.D., Head of Health Care Royalty and Income strategy at KKR. “We’re proud to help support Aimmune’s important work, especially as the company prepares to launch what could be the world’s first approved medical treatment for peanut allergy.”

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™ is AR101. Aimmune intends to submit a regulatory filing for marketing approval of AR101 in Europe during the first half of 2019 based on data from Aimmune’s pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. Aimmune has filed an IND application for its second product, AR201, for the treatment of egg allergy and intends to start a randomized Phase 2 clinical trial in the first half of 2019. For more information, please see www.aimmune.com.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding the timing and availability of the full amount of proceeds under the loan agreement; Aimmune’s expectations regarding the sufficiency of its cash resources; Aimmune’s expectations regarding the potential benefits of AR101; Aimmune’s expectations regarding the potential commercialization of AR101, including the timing of a potential approval of AR101; Aimmune’s expectations on the timing of initiating a Phase 2 clinical trial for AR201; Aimmune’s expectations on regulatory submissions for marketing approval of AR101 for peanut allergy in Europe; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the satisfaction of closing conditions for each subsequent tranche of the loan agreement; the expectation that Aimmune will need additional funds to finance its operations; Aimmune’s or any of its collaborative partners’ ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; Aimmune’s reliance on third parties for the manufacture of Aimmune’s product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune’s most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This press release concerns AR101, a product that is under clinical investigation, and AR201, a product that Aimmune expects will be under clinical investigation in 2019. Neither AR101 nor AR201 has been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). AR101 and AR201 are currently limited to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190104005280/en/

Source: Aimmune Therapeutics, Inc.

Aimmune
Investors
Laura Hansen, Ph.D.
(650) 396-3814
lhansen@aimmune.com

Media
Alison Marquiss
(650) 376-5583
amarquiss@aimmune.com

KKR
Kristi Huller or Samantha Norquist
(212) 750-8300
media@KKR.com

Frankfurt (Germany), 4 January 2019 – The Smaller Mid-Cap Fund (“TSM”) advised by Triton (“Triton”) has signed an agreement to invest in Deutsche Radiologie Holding (“DRH”), alongside with the current shareholders consisting of the owners of Tempus Capital and the management team. Terms of conditions are not disclosed.

DRH was founded in 2017 and offers radiologists and radiotherapists flexible and professional succession solutions. DRH is a strong and experienced partner for successful owners. The experienced team ensures a technically competent and reliable handover process and a long-term preservation of the owner’s work.

The Triton Smaller Mid-Cap Fund seeks to invest in mid-cap companies in the sectors industrials, business services, consumer and health. This transaction is the 7th investment since inception of the fund Mid 2017.

“Succession planning is a highly important topic for owners of small and mid-sized companies across all sectors and regions we operate in. DRH is addressing the increasing demand for succession solutions with a professional offering, tailor made to its target group. We are pleased to work with DRH, its management team and the owners of Tempus Capital on the way forward”, comments Andi Klein, TSM Investment Advisory Committee Member and Investment Advisory Professional to the Triton funds.

Steffen Dauster, CEO and founder of DRH, adds: “Given the large demand for flexible succession solutions in our area and our strong growth profile, we welcome Triton as a new partner. We are excited about the future prospects of DRH and the continued partnership with all our stakeholders.”

About Triton
The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe, focusing on businesses in the Industrial, Business Services and Consumer/Health sectors.

Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth. The 38 companies currently in Triton’s portfolio have combined sales of around € 13.1 billion and around 85,000 employees.

The Triton funds are advised by dedicated teams of professionals based in Germany, Sweden, Norway, Finland, Denmark, Italy, the United Kingdom, the United States, China, Luxembourg and Jersey.

For more information: www.triton-partners.com

About DRH
Deutsche Radiologie Holding was founded 2017. Headquartered in Frankfurt / Main, DRH accompanies radiological, nuclear medicine and radiotherapeutic practices on the path to succession planning as a financially strong investor and professional management partner. The team has many years of experience and extensive practical expertise in this field.

For more information: www.deutsche-radiologie.com

Press Contacts:

Triton
Marcus Brans
Phone: +49 69 921 02204

Deutsche Radiologie Holding
Edina Sabanovic
esabanovic@deutsche-radiologie.com

South San Francisco, Calif. – January 3, 2019 – Verily, an Alphabet company, today announced a $1
billion investment round, led by Silver Lake, as it advances plans on business strategies that are additive
and complementary to its current life sciences portfolio. Other new investors in the round include Ontario
Teachers’ Pension Plan and other global investment management firms. The capital raised will support
growth in key strategic areas, including investments in strategic partnerships, global business
development opportunities, and potential acquisitions. Financial terms of the transaction were not
disclosed. Ruth Porat, chief financial officer at Alphabet, and Egon Durban, managing partner and
managing director of Silver Lake, will be nominated to join Verily’s operating board.
“We are taking external funding to increase flexibility and optionality as we expand on our core strategic
focus areas,” said Andrew Conrad, CEO of Verily. “Adding a well-rounded group of seasoned investors,
led by Silver Lake, will further prepare us to execute as healthcare continues the shift towards evidence
generation and value-based reimbursement models.”
“Verily’s unique capabilities, world-class partnerships and bold vision are enabling the company to tackle
the most significant problems impacting global healthcare,” said Egon Durban. “We look forward to
working with Andy and the entire Verily team in their mission to use cutting-edge science and technology
to change the paradigm of care delivery and improve clinical outcomes.”
Goldman Sachs & Co. LLC acted as financial advisor to Verily.

About Verily Life Sciences
Verily is a life sciences research and engineering organization focused on improving healthcare outcomes
by applying the latest scientific and technological advances to significant problems in health and biology.
By combining unparalleled capabilities in data organization and analytics services with robust scientific
and product engineering expertise, Verily is targeting the dual objectives of creating tools and
user-friendly platforms that capture a deeper and broader set of health data and organizing the data so that
it is useful and actionable. Verily partners with leading life sciences, medical device and government
organizations to leverage deep domain expertise and resources that enable exponentially faster
development, meaningful advancements and deployment at scale. For more information, visit
www.verily.com.

About Silver Lake
Silver Lake is the global leader in technology investing, with about $45.5 billion in combined assets under
management and committed capital and a team of approximately 100 investment and value creation
professionals located in Silicon Valley, New York, London and Hong Kong. Silver Lake’s portfolio of
investments collectively generates more than $225 billion of revenue annually and employs more than
390,000 people globally. For more information about Silver Lake and its entire portfolio, please visit
www.silverlake.com.

Press Contact:
Carolyn Wang
carolynwang@verily.com
415-736-2437

3i Group plc (“3i”) today announces that Cirtec Medical (“Cirtec”), a strategic outsourcing partner for complex medical devices in which 3i invested in August 2017, is acquiring Metrigraphics, a leading manufacturer of ultra-high precision, custom micron-scale circuits and components for the medical devices industry and other critical applications.

Metrigraphics combines core technologies of thin film sensor substrate manufacturing with their proprietary processes to provide ultra-miniature components that increase the performance, accuracy, and reliability of state-of-the-art medical and wearable devices.  The Company serves a number of fast growing medical device segments, including continuous glucose monitoring, advanced drug delivery, active medication management and life science instruments. The acquisition also further strengthens Cirtec’s relationship with market leading and pioneering OEMs serving these device segments.

Metrigraphics has approximately 175 employees. The company is ISO 9001 certified and is based in a 46,000 sq. ft. facility in Lowell, Massachusetts.

Brian Highley, CEO, Cirtec, commented:

“This is a significant acquisition that fits perfectly with Cirtec’s focus on active implantables and aligns well with our strategy of expanding our capabilities serving minimally invasive interventional therapeutic products.  We plan to continue to enhance our capabilities to support our core customers, including those in the neuromodulation and active implantable markets, and to increase our investment in wearables and other biomedical applications.”

Richard Relyea, Partner, 3i Private Equity, added:

“The acquisition of Metrigraphics builds upon the recent acquisition of Cactus Semiconductor and further expands the company’s product portfolio of cutting edge and technically challenging medical device components.  Metrigraphics also diversifies the company’s device exposures with additional therapeutic markets poised for long-term growth.  We are excited to partner with an organisation that has such strong capabilities and relationships with innovative OEMs.”

This transaction represents Cirtec’s fourth completed acquisition since 3i’s investment, and will be funded from the company’s own resources.

-Ends-

Download this press release   

For further information, contact: 

3i Group plc

Utrecht (The Netherlands), Boston (United States) – Ablative Solutions, Inc. (Kalamazoo, Michigan), a medtech company pioneering new approaches for the treatment of hypertension, today announced the first close of its USD 77 million Series D funding round. The round was led by Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor. Existing investors, including Michigan Accelerator Fund, Novus Biotechnology and other individual investors rounded out the financing.

Funds from the round will be used to complete clinical trials in support of U.S. and European regulatory submissions for the company’s minimally invasive renal denervation technology designed to help reduce blood pressure for people with uncontrolled hypertension.

Ablative Solutions’ alcohol-mediated renal denervation procedure is performed using the investigational Peregrine System Kit™, which is engineered to target nerves known to influence the body’s regulation of blood pressure. The Peregrine Kit delivers dehydrated alcohol in small doses directly to the space outside of the renal artery to block the overactive signaling of the sympathetic nerves. This targeted treatment is designed to be performed in a rapid, straightforward procedure with minimal pain or discomfort for the patient.

Drug therapy and lifestyle changes are the most common treatments for hypertension. Medication non-adherence remains a serious and underappreciated limitation of drug therapy. More than half of those treated do not achieve their target blood pressure, highlighting the need for improved therapeutic options.

About the Peregrine System Infusion Catheter
The Peregrine System Infusion Catheter has 510(k) clearance for the infusion of diagnostic and therapeutic agents into the perivascular area of the peripheral vasculature. The Peregrine System Infusion Catheter is CE marked for the infusion of a neurolytic agent to achieve a reduction in systemic blood pressure in hypertensive patients.

About Ablative Solutions
Ablative Solutions, Inc., based in Kalamazoo, Mich., and San Jose, Calif., was founded in 2011 with a vision to address the unmet need of hypertension. Ablative Solutions’ approach targets the overactive sympathetic nervous system, which may play a role in hypertension, heart failure, kidney disease, metabolic syndrome and sleep apnea. The Peregrine System Infusion Catheter provides physicians with a way to infuse diagnostic and therapeutic agents into the area surrounding the renal artery, where sympathetic nerves are located. The Peregrine System Kit is currently being investigated as a treatment for hypertension in conjunction with antihypertensive medications. For more information visit ablativesolutions.com.

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing EUR 1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in therapeutics, medtech and digital health. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable lower mid-market European healthcare services companies with a focus on the Benelux and DACH region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. The venture & growth fund is currently investing out of Gilde Healthcare IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility. For more information, visit the company’s website at gildehealthcare.com.